Drug Database
Back to search

Poland· PL-100488432

Tetralysal

A lymecycline product containing lymecyclinum, registered in Poland by Aga Kommerz spol. s r.o.. The same ATC class is registered in 12 of our 19 countries.

ATC J01AA04

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedTetralysalATCJ01AA04REGISTER NO.PL-100488432PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about lymecyclinumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Lymecycline is registered in 12 of 19 countries.

Countries holding a registration under ATC J01AA04 (lymecycline), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose
Search lymecycline products by name

Lymecycline · ATC J01AA04

12 / 19 countries

  • Belgiumprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of lymecycline costs, country by country.

Normalised to the WHO defined daily dose (0.6 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Lymecycline · price per daily dose (0.6 g)

USD · FX 28 Sept 2026

  • CH Switzerland$2.52
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Lymecyclinum
Manufacturer
Aga Kommerz spol. s r.o.
Country
Poland (PL)
ATC code
J01AA04
ATC class
Lymecycline
Defined daily dose
0.6 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909991523848
  • gtin
    05909991523855

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

53 interactions on record for lymecycline.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check lymecycline against other medicinesHow interaction checks work

Lymecycline · interactions on record

53 records

53 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Lymecycline in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lymecycline products

Authorised across Europe · EMA

The same active substance is authorised in 13 EEA countries. Names it is sold under:

  • Austria · Cyclopel
  • Belgium · Lymecycline (Entsprechend Tetracyclin-Base) Brown & Burk, Lymecycline (Équivalent À Tétracycline Base) Brown & Burk
  • Denmark · Lymecyclin " Brown & Burk ", Lymecyclin Actavis
  • Finland · Lymecycline Brown & Burk, Lymecycline Ratiopharm
  • France · Lymecycline Arrow, Tetralysal
  • United Kingdom (Northern Ireland) · Lymecycline, Lymecycline Actavis
  • Hungary · Tetralysal
  • Ireland · Lycimor, Rimicorim
  • Iceland · Lymecycline Actavis
  • Malta · Tetralysal
  • Norway · Lymecyclin Actavis, Lymecycline Brown & Burk
  • Portugal · Limeciclina Atral
  • Sweden · Lymecycline Actavis, Lymecycline Glenmark

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ea797769-471a-402b-bf00-8361746a1acd
GET /v1/drugs/ea797769-471a-402b-bf00-8361746a1acd?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Kapsułki twarde",
  "source": "urpl",
  "strength": "300 mg",
  "packaging": "05909991523848 ¦ Rp ¦ 151694\n16 kaps.\n05909991523855 ¦ Rp ¦ 151695\n28 kaps.",
  "substance": "Lymecyclinum 300 mg",
  "common_name": "Lymecyclinum",
  "pl_product_id": "100488432",
  "pozwolenie_nr": "224/23",
  "auth_procedure": "IR",
  "authorisation_validity": "2028-10-10"
}
API referenceMCP serverPlans

See everything about lymecycline.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console